U S PHYSICAL THERAPY INC /NV

ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. On September 15, 2026, U.S. Physical Therapy Inc.’s (“Company”) Board of Directors (the “Board”) approved the appointment of Ms. Myra Davis to serve as a member of the Board, effective October 1, 2026. Myra Davis, 61, currently serves as the Executive Vice President and Chief Information Innovation Officer at Texas Children’s Hospital, a position she held since 2023. She has served in a variety of information services and information technology roles at Texas Children’s Hospital since 2003, including Senior Vice President and Chief Information and Innovation Officer from 2019 to 2023 and Chief Information Officer from 2009 through 2019. In this role, Ms. Davis leads enterprise technology strategy, digital transformation, innovation, and information services for one of the nation’s leading pediatric healthcare organizations. With more than two decades of CIO-level healthcare leadership, Ms. Davis is recognized for advancing secure, scalable technology solutions, cultivating high-performing teams, and positioning technology as a catalyst for innovation, operational excellence, and improved care delivery. Ms. Davis also serves on the Board of Directors of Werfen, a global medical diagnostics company, and on the Advisory Board of Healthcare Information Management Systems Society of America. Ms. Davis received a Bachelor of Science degree in Computer Information Processing from Loyola University, and a Master of Science degree in Software Design and Development from the University of St. Thomas. As of the date of this Current Report on Form 8-K, Ms. Davis has not been appointed to any committee of the Board. Upon joining the Board on October 1, 2026, Ms. Davis will be entitled to receive an annual cash retainer and annual equity grant, both of which will be based on the terms, and in the amounts, as determined in accordance with the processes described in the “Director Compensation” section of the Company’s definitive proxy statement filed with the Securities and Exchange Commission (the “SEC”) on April 16, 2026. There are no arrangements or understandings between Ms. Davis and any other person pursuant to which she was selected to serve as a director. There are no related-party transactions between Ms. Davis and the Company that are reportable under Item 404(a) of Regulation S-K.